ADVERTISEMENT
Podcasts
Hannah Linden, MD, Highlights AMEERA-1 Data for ER+/HER2- Metastatic Breast Cancer
11/16/2021
Dr Linden, Seattle Cancer Care Alliance, Seattle, WA, shares encouraging results from the AMEERA-1 trial of SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual SABCS Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement